How will you use REGEN-COV (casirivimab/imdevimab-monoclonal antibody treatment recently approved under EUA as post-exposure prophylaxis for Covid) in rheumatic patients on immunosuppressive therapy?

Like most other treatments, I've tried to triage use of REGEN-COV post-exposure prophylaxis (PEP) based on the other risk factors that a patient has:

The NEJM study published by O'Brien et al. PMID 34347950 did show marked benefit in REGEN-COV post-exposure prophylaxis vs. placebo in the (a) decreasi...

I have a rheumatoid arthritis patient with ILD whose husband had COVID. She could not get post-exposure prophylaxis in Texas without a positive test. I appealed to several centers. We did get her husband treated with monoclonal antibodies to decrease the viral load. She self-tested daily at home for...